MAPT and dementia: First, previous research indicates that, compared to total tau, phosphorylated tau has higher prognostic utility regarding clinical outcomes of AD dementia.50,51 Total tau is a rather broad, aspecific marker that is not exclusively associated with dementia.52 At the time of biomarker assessment, tau assessments were not yet widely implemented53 and only recently, the research focus shifted to more dementia-specific phosphorylated tau markers.54 Nonetheless, studies indicate that total tau can still provide added prognostic value, especially if combined with other biomarkers.55